WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

$$A—L—Y \quad (I)$$

wherein: L is selected from the group consisting of:



(Ia),



(Ib),



(Ic) and



(Id);

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted 5-18 membered heterocyclyl;

Y is selected from the group consisting of an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{1a}, R^{1b}, R^{1c} and R^{1d} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{2a} and R^{2a1} are each independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or

AMENDED SHEET
IPEA/AU

R^{2a1} is hydrogen, and R^{1a} and R^{2a} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl,

R^{2b} and R^{2b1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or

R^{2b1} is hydrogen, and R^{1b} and R^{2b} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl;

R^{2c} and R^{2c1} are each independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy;

R^{2d} and R^{2d1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy;

-------- between X^{1a} and X^{2a} represents a single or double bond between X^{1a} and X^{2a}; ---------- between X^{2a} and X^{3a} represents a single or double bond between X^{2a} and X^{3a}; provided that ---------- between X^{1a} and X^{2a} and -------- between X^{2a} and X^{3a} cannot be both double bonds and at least one of -------- is a double bond;

when -------- between X^{1a} and X^{2a} represents a double bond and -------- between X^{2a} and X^{3a} is a single bond, then X^{1a} is N or CR^{4a1}, X^{2a} is N or CR^{5a} and X^{3a} is NR^{6a1}, C(=O) or $CR^{6a2}R^{6a3}$; and when -------- between X^{1a} and X^{2a} represents a single bond and -------- between X^{2a} and X^{3a} is a double bond, then X^{1a} is NR^{4a} or $CR^{4a2}R^{4a3}$, X^{2a} is N or CR^{5a} and X^{3a} is N or CR^{6a}; or

X^{1a}, X^{2a} and X^{3a} are each independently C, N or C(=O), and form a ring or ring system selected from an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl by joining X^{1a} and X^{3a} together; with the proviso that the valencies of X^{1a}, X^{2a} and X^{3a} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl, and X^{1a}, X^{2a} and X^{3a} are uncharged;

AMENDED SHEET
IPEA/AU

R^{3a} is selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and ,

R^{3a1} is selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3a} and R^{3a1} cannot be both hydrogen; or

R^{3a} and R^{3a1} together form =N-OR^a; or R^{3a} and R^{3a1} together with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^{4a}, R^{4a1}, R^{4a2} and R^{4a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{5a} and R^{5a1} are each independently be hydrogen or an unsubstituted C_{1-4} alkyl;

R^{6a} and R^{6a1} are each independently hydrogen, an optionally substituted C_{1-4} alkyl or an optionally substituted alkoxyalkyl;

R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

X^{1b}, X^{2b} and X^{3b} are each independently C, N, O or C(=O), and form indicates a bi-cyclic ring selected from an optionally substituted 9-membered bi-cyclic heteroaryl, an optionally substituted 10-membered bi-cyclic heteroaryl, an optionally substituted 9-membered bi-cyclic heterocyclyl and an optionally substituted 10-membered bi-cyclic heterocyclyl by joining X^{1b} and X^{3b} together, wherein ---------- between X^{1b} and X^{2b} represents a single or double bond between X^{1b} and X^{2b}; ---------- between X^{2b} and X^{3b} represents a single or double bond between X^{2b} and X^{3b}; and provided that at least one of X^{1b}, X^{2b} and X^{3b} comprises a nitrogen atom and both ---------- cannot be double bonds; with the proviso that the valencies of X^{1b}, X^{2b} and

AMENDED SHEET
IPEA/AU

X^{3b} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl; and X^{1b}, X^{2b} and X^{3b} are uncharged;

R^{3c} and R^{3c1} are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3c} and R^{3c1} cannot be both hydrogen; or R^{3c} and R^{3c1} together form =N-OR^c; or R^{3c} and R^{3c1} together with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^a and R^c are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{4c} and R^{5c} are taken together to form an unsubstituted aryl, an unsubstituted heteroaryl or an optionally substituted heterocyclyl;

Z^c is N or CH;

m^d is 0 or 1; and

ring B^d is an optionally substituted C_5 cycloalkyl;

ring B^{d1} is an optionally substituted pyridinyl; and

provided that when L is Formula (IIc), then Y is absent; and

provided that the compound is not .

2. The compound of Claim 1, wherein L is Formula (Ia).

3. The compound of Claim 2, wherein X^{1a} is CR^{4a1} or $CR^{4a2}R^{4a3}$, X^{2a} is N, and X^{3a} is CR^{6a} or $CR^{6a2}R^{6a3}$.

4. The compound of Claim 2, wherein -------- between X^{1a} and X^{2a} is a single bond, - ------- between X^{2a} and X^{3a} is a double bond, X^{1a} is $CR^{4a2}R^{4a3}$, X^{2a} is N, and X^{3b} is CR^{6a}.

AMENDED SHEET
IPEA/AU

5. The compound of Claim 2, wherein -------- between X^{1a} and X^{2a} is a double bond, -------- between X^{2a} and X^{3a} is a single bond, X^{1a} is CR^{4a1}, X^{2b} is N, and X^{3b} is $CR^{6a2}R^{6a3}$.

6. The compound of Claim 2, wherein $-X^{1a}$------X^{2a}------$X^{3a}-$ is $-CH_2-N=CH-$ or $-CH=N-CH_2-$.

7. The compound of Claim 2, wherein $-X^{1a}$------X^{2a}------$X^{3a}-$ is $-N=N-CH_2-$, $-N=CH-CH_2-$ or -N=CH-NH-.

8. The compound of Claim 2, wherein $-X^{1a}$------X^{2a}------$X^{3a}-$ is $-CH_2-CH=N-$, -NH-CH=NH- or -NH-N=CH-.

9. The compound of Claim 1, wherein L is Formula (Ia1):



10. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} is a ring or ring system is an optionally substituted aryl.

11. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} is a ring or ring system is an optionally substituted mono-cyclic heteroaryl or an optionally substituted bi-cyclic heteroaryl.

12. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} is a ring or ring system is an optionally substituted mono-cyclic heterocyclyl or an optionally substituted bi-cyclic heterocyclyl.

13. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} is a ring or ring system selected from the group consisting of an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally

AMENDED SHEET
IPEA/AU

substituted , an optionally substituted , an optionally substituted , an optionally substituted an optionally substituted , an optionally substituted  an optionally substituted , an optionally substituted  an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein R^{A1}, R^{A2}, R^{A3} and R^{A4} is each independently hydrogen or an unsubstituted C_{1-6} alkyl; each ------ is independently absent or a bond; each R^{A5}, each R^{A6}, each R^{A7} is an unsubstituted C_{1-6} alkyl, halogen, hydroxy, amino, mono-substituted amino, di-substituted amino or –NH-S(=O)C_{1-4} alkyl; and R^{A8} is hydrogen or an unsubstituted C_{1-6} alkyl.

14. The compound of Claim 1, wherein L is Formula (Ia2):

AMENDED SHEET
IPEA/AU



wherein R^{7a1}, R^{7a2} and R^{7a3} are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl, an optionally substituted O-amido and an optionally substituted C-carboxy.

15. The compound of Claim 14, wherein R^{7a1} is a C_{1-4} alkoxy, and R^{7a2} and R^{7a3} are both hydrogen.

16. The compound of Claim 14, wherein R^{7a1} is a hydrogen, R^{7a2} is an optionally substituted C_{1-4} alkyl, and R^{7a3} is hydrogen.

17. The compound of Claim 16, wherein the substituted C_{1-4} alkyl of R^{7a2} is substituted with a substituent selected from the group consisting of halo, hydroxy, C_{1-4} alkoxy, an optionally substituted aryl(C_{1-4} alkyl), an optionally substituted C-carboxy, amino, an optionally substituted mono-substituted amino, an optionally substituted di-substituted amino, an optionally substituted C-amido, an optionally substituted N-amido, an optionally substituted N-carbamyl, an optionally substituted N-sulfonamido, an optionally substituted urea, an optionally substituted amidine and an optionally substituted acetylurea.

18. The compound of Claim 14, wherein R^{7a1} is a hydrogen, R^{7a2} is an optionally substituted heterocyclyl, and R^{7a3} is hydrogen

AMENDED SHEET
IPEA/AU

19. The compound of Claim 14, wherein R^{7a1} is a mono-substituted amino, and R^{7a2} and R^{7a3} are both hydrogen.

20. The compound of Claim 1, wherein L is Formula (Ia3):



wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted cycloalkyl an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and R^{8a3} is selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl and an optionally substituted C-carboxy.

21. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered cycloalkyl or an optionally substituted 6-membered cycloalkyl.

22. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted aryl.

23. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered heteroaryl.

24. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heterocyclyl or an optionally substituted 6-membered heterocyclyl.

AMENDED SHEET
IPEA/AU

25. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted , an optionally substituted  or an optionally substituted ; wherein each ------ is independently absent or a bond; each R^{A5}, each R^{A6}, each R^{A7} is halogen, an unsubstituted C_{1-6} alkyl, hydroxy, amino, an optionally substituted mono-substituted amino, an optionally substituted di-substituted amino, $(CH_2)_{1-4}OH$, $-(CH_2)_{1-4}NH_2$ or N-sulfinamido (for example, $-NH-S(=O)C_{1-4}$ alkyl), or two R^{A5}, two R^{A6} or two R^{A7} are taken together to form an optionally substituted 5- membered ring to an optionally substituted 6-membered ring; and R^{A8} is hydrogen or an unsubstituted C_{1-6} alkyl.

26. The compound of any one of Claims 2-25, wherein R^{1a} can be hydrogen.

27. The compound of any one of Claims 2-25, wherein R^{1a} can be an unsubstituted C_{1-4} alkyl.

28. The compound of any one of Claims 2-27, wherein R^{2a} and R^{2a1} are both hydrogen.

29. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an unsubstituted C_{1-4} alkyl.

30. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

31. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

32. The compound of any one of Claims 2-27, wherein R^{2a1} is hydrogen, and R^{1a} and R^{2a} are joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl.

33. The compound of any one of Claims 2-27, wherein R^{2a} and R^{2a1} are both an unsubstituted C_{1-4} alkyl.

AMENDED SHEET
IPEA/AU

34. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

35. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is hydroxy.

36. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen, -O-carboxy, an unsubstituted heteroaryl and an optionally substituted heterocyclyl.

37. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{1-4} alkyl.

38. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{2-4} alkynyl.

39. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is CF_3.

40. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is CHF_2.

41. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is CF_3.

42. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is CHF_2.

43. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{3-6} cycloalkyl.

44. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is an unsubstituted C_{3-6} cycloalkyl.

45. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} are both halogen.

46. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is unsubstituted C_{1-4} alkyl.

AMENDED SHEET
IPEA/AU

47. The compound of any one of Claims 2-33, wherein R^{3a} is an unsubstituted C_{1-4} alkoxy, and R^{3a1} is an unsubstituted C_{1-4} alkyl.

48. The compound of any one of Claims 2-33, wherein R^{3a1} is a substituted C_{1-4} alkyl substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mono-substituted amino, di-substituted amino, -N-amido, an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl; and the other of R^{3a} and R^{3a1} is hydroxy.

49. The compound of any one of Claims 2-33, wherein one of R^{3a} and R^{3a1} is an optionally substituted mono-cyclic heteroaryl or an optionally substituted mono-cyclic heterocyclyl; and the other of R^{3a} and R^{3a1} is hydroxy.

50. The compound of Claim 49, wherein one of R^{3a} and R^{3a1} is selected from the group consisting of an optionally substituted imidazole, an optionally substituted pyrazole, an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted morpholine, an optionally substituted triazole, an optionally substituted piperazinone and an optionally substituted azetidine; and the other of R^{3a} and R^{3a1} is hydroxy.

51. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} together form $N=OR^a$.

52. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} are join together with the atom to which they are attached to form an optionally substituted 3 to 6 membered ring.

53. The compound of Claim 1, wherein L is Formula (Ib):



54. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted 9-membered bi-cyclic heteroaryl or an optionally substituted 10-membered bi-cyclic heteroaryl.

55. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted 9-membered bi-cyclic heterocyclyl or an optionally substituted 10-membered bi-cyclic heterocyclyl.

AMENDED SHEET
IPEA/AU

56. The compound of any one of Claims 53-55, wherein X^{1b} is C, X^{2b} is N and X^{3b} is C.

57. The compound of any one of Claims 53-55, wherein X^{1b} is N, X^{2b} is N and X^{3b} is C.

58. The compound of any one of Claims 53-55, wherein X^{1b} is N or C, X^{2b} is C(=O) or O and X^{3b} is N or C.

59. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein each ----- is independently absent or a bond; each R^{B1}, each R^{B2} and each R^{B3} is an unsubstituted C_{1-6} alkyl, halogen, hydroxy, amino, mono-substituted amino, di-substituted amino or –NH-S(=O)C_{1-4} alkyl; and R^{B4} is hydrogen or an unsubstituted C_{1-6} alkyl.

60. The compound of Claim 1, wherein L is Formula (Ib1):



wherein: the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted cycloalkenyl an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and R^{4b3} is selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally

AMENDED SHEET
IPEA/AU

substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl and an optionally substituted C-carboxy.

61. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered cycloalkenyl or an optionally substituted 6-membered cycloalkenyl.

62. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted aryl.

63. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered heteroaryl.

64. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heterocyclyl or an optionally substituted 6-membered heterocyclyl.

65. The compound of any one of Claims 52-64, wherein R^{1b} is hydrogen.

66. The compound of any one of Claims 53-64, wherein R^{1b} is unsubstituted C_{1-4} alkyl.

67. The compound of any one of Claims 63-56, wherein R^{2b} and R^{2b1} are both hydrogen.

68. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an optionally substituted C_{1-4} alkyl.

69. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

70. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

71. The compound of any one of Claims 53-66, wherein R^{2b1} is hydrogen, and R^{1b} and R^{2b} are joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl.

72. The compound of any one of Claims 53-66, wherein R^{2b} and R^{2b1} are both an optionally substituted C_{1-4} alkyl.

AMENDED SHEET
IPEA/AU

73. The compound of Claim 1, wherein L is Formula (1c):



74. The compound of Claim 73, wherein R^{1c} is hydrogen.

75. The compound of Claim 73, wherein R^{1c} is an unsubstituted C_{1-4} alkyl.

76. The compound of any one of Claims 73-75, wherein R^{2c} and R^{2c1} are both hydrogen.

77. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an unsubstituted C_{1-4} alkyl.

78. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

79. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

80. The compound of any one of Claims 73-75, wherein R^{2c} and R^{2c1} are both an unsubstituted C_{1-4} alkyl.

81. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

82. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is hydroxy.

83. The compound of any one of Claims 73-80, wherein R^{3c} is hydroxy, and R^{3c1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

84. The compound of any one of Claims 73-80, wherein R^{3c} is hydroxy, and R^{3c1} is an unsubstituted C_{1-4} alkyl.

85. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} are both halogen.

AMENDED SHEET
IPEA/AU

86. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is unsubstituted C_{1-4} alkyl.

87. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} together form $N=OR^c$.

88. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} join together with the atom to which they are attached to form an optionally substituted 3 to 6 membered ring.

89. The compound of any one of Claims 73-88, wherein Z^c is N.

90. The compound of any one of Claims 73-88, wherein Z^c is CH.

91. The compound of any one of Claims 73-90, wherein R^{4c} and R^{5c} are taken together to form an unsubstituted aryl or an unsubstituted heteroaryl.

92. The compound of any one of Claims 73-90, wherein R^{4c} and R^{5c} are taken together to form an optionally substituted heterocyclyl.

93. The compound of Claim 92, wherein the optionally substituted heterocyclyl is an optionally substituted,  wherein * each indicate a point of attachment to the piperdinyl ring.

94. The compound of Claim 1, wherein L is Formula (Id):



95. The compound of Claim 94, wherein m^d is 0 or 1.

96. The compound of Claim 94, wherein ring B^d is an optionally substituted C_5 cycloalkyl.

97. The compound of any one of Claims 94-96, wherein R^{1d} is hydrogen.

98. The compound of any one of Claims 94-96, wherein R^{1d} is unsubstituted C_{1-4} alkyl.

99. The compound of any one of Claims 94-98, wherein R^{2d} and R^{2d1} are both hydrogen.

AMENDED SHEET
IPEA/AU

100. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an optionally substituted C_{1-4} alkyl.

101. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

102. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

103. The compound of any one of Claims 94-98, wherein R^{2c} and R^{2c1} are both an optionally substituted C_{1-4} alkyl.

104. The compound of any one of Claims 1-103, wherein A is an optionally substituted aryl.

105. The compound of Claim 104, wherein A is an optionally substituted phenyl.

106. The compound of Claim 105, wherein A is a phenyl substituted with one or more substituents selected from the group consisting of: an unsubstituted C_{1-4} alkyl, an optionally substituted C_{1-4} alkyl, cycloalkyl, hydroxy, an optionally substituted C_{1-4} alkoxy, C_{1-4} alkoxy, halogen, haloalkyl, an optionally substituted haloalkoxy, nitro, amino, mono-substituted amino, di-substituted amine, -O-amido, sulfenyl, alkyoxyalkyl, an optionally substituted aryl, an optionally substituted mono-cyclic heteroaryl, an optionally substituted mono-cyclic heterocyclyl, an optionally substituted aryl(C_{1-4} alkyl), an optionally substituted monocyclic heteroaryl(C_{1-4} alkyl), an optionally substituted monocyclic heterocyclyl(C_{1-4} alkyl), hydroxyalkyl and aminoalkyl.

107. The compound of Claim 105, wherein A is a phenyl substituted with one or more substituents selected from the group consisting of: methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, phenoxy, bromo, chloro, fluoro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, N,N-di-methyl-amine, N,N-di-ethyl-amine. N-methyl-N-ethyl-amine, N-methyl-amino, N-ethyl-amino, amino, N-amido , N-sulfonamido, alkylthio, an optionally substituted phenyl, an optionally substituted imidazole, an optionally substituted morpholinyl, an optionally substituted pyrazole, an optionally substituted pyrrolidinyl, an optionally substituted pyridinyl, an optionally substituted piperidinyl, an optionally substituted piperidinone, an optionally substituted pyrrolidinone, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted 1,2,4-oxadiazole, $-(CH_2)_{1-4}$-OH, $-(CH_2)_{1-2}$-$NH(CH_3)$, an optionally substituted $-(CH_2)_{1-2}$-

AMENDED SHEET
IPEA/AU

imidazole, an optionally substituted -$(CH_2)_{1-2}$-pyrrolidinone, an optionally substituted -$(CH_2)_{1-2}$-imidazolidinone, -$O(CH_2)_2$-NH_2, –$O(CH_2)_2$-$NH(CH_3)$, –$O(CH_2)_2$-$N(CH_3)_2$, -O-$(CH_2)_{2-4}$OH, -$O(CH_2)_2OCH_3$, an optionally substituted -$O(CH_2)_{0-2}$-cyclopentanone, an optionally substituted -$O(CH_2)_{0-2}$pyrrolidinone, an optionally substituted -$O(CH_2)_{0-2}$-morpholinyl, an optionally substituted -$O(CH_2)_{0-2}$-triazole, an optionally substituted -$O(CH_2)_{0-2}$-imidazole, an optionally substituted -$O(CH_2)_{0-2}$-pyrazole, an optionally substituted -$O(CH_2)_{0-2}$-tetrahydrofuran, an optionally substituted -$O(CH_2)_{0-2}$-pyrrolidinone, an optionally substituted -$O(CH_2)_{0-2}$-tetrazole, an optionally substituted -$O(CH_2)_{0-2}$-tetrazolone,



and

108. The compound of any one of Claims 105-107, wherein A is a di-substituted phenyl.

AMENDED SHEET
IPEA/AU

109. The compound of any one of Claims 1-103, wherein A is an optionally substituted cycloalkyl or an optionally substituted cycloalkenyl.

110. The compound of any one of Claims 1-103, wherein A is an optionally substituted aryl(C_{1-2} alkyl).

111. The compound of any one of Claims 1-103, wherein A is an optionally substituted heteroaryl.

112. The compound of Claim 111, wherein the optionally substituted heteroaryl is selected from the group consisting of: an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted quinolone, an optionally substituted imidazole, an optionally substituted oxazole, an optionally substituted isoxazole, an optionally substituted benzoimidazole, an optionally substituted benzooxazole, an optionally substituted benzothiazole and an optionally substituted imidazo[1,2-a]pyrimidine.

113. The compound of any one of Claims 1-103, wherein A is an optionally substituted 5-18 membered heterocyclyl.

114. The compound of Claim 113, wherein the optionally substituted 5-18 membered heterocyclyl is selected from the group consisting of: an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , optionally substituted  and an optionally substituted .

115. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted aryl.

AMENDED SHEET
IPEA/AU

116. The compound of Claim 115, wherein Y is a mono-substituted phenyl.

117. The compound of Claim 116, wherein Y is a di-substituted phenyl.

118. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted mono-cyclic heteroaryl.

119. The compound of Claim 118, wherein the optionally substituted mono-cyclic heteroaryl is selected from the group consisting of: an optionally substituted imidazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted pyridine, an optionally substituted pyrazole, an optionally substituted oxazole, an optionally substituted isoxazole and an optionally substituted thiazole.

120. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted bi-cyclic heteroaryl.

121. The compound of Claim 120, wherein the optionally substituted bi-cyclic heteroaryl is selected from the group consisting of: an optionally substituted benzothiophene, an optionally substituted benzofuran, an optionally substituted indole, an optionally substituted quinoline, an optionally substituted isoquinoline, an optionally substituted benzooxazole, an optionally substituted benzoisoxazole, an optionally substituted benzoisothiazole, an optionally substituted benzothiazole, an optionally substituted benzoimidazole, an optionally substituted benzotriazole, an optionally substituted 1H-indazole, an optionally substituted 2H-indazole, an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted

AMENDED SHEET
IPEA/AU


, an optionally substituted 
, an optionally substituted 
and an optionally substituted 
.

122. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted heterocyclyl.

123. The compound of Claim 122, wherein the optionally substituted heterocyclyl is selected from the group consisting of: an optionally substituted pyridinone, an optionally substituted 
, an optionally substituted 
, an optionally substituted 
and an optionally substituted 
.

124. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted cycloalkenyl.

125. The compound of any one of Claims 1-72, 92-115 or 118-124, wherein Y is unsubstituted.

126. The compound of any one of Claims 1-72 or 94-124, wherein Y is substituted with one or more R^B, wherein each R^B is independently selected from the group consisting of: cyano, halogen, an optionally substituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an optionally substituted aryl, an optionally substituted 5 or 6 membered heteroaryl, an optionally substituted 5 or 6 membered heterocyclyl, hydroxy, C_{1-4} alkoxy, alkoxyalkyl, C_{1-4} haloalkyl, haloalkoxy, an unsubstituted acyl, an optionally substituted –

AMENDED SHEET
IPEA/AU

C-carboxy, an optionally substituted –C-amido, sulfonyl, carbonyl, amino, mono-substituted amine, di-substituted amine and .

127. The compound of any one of Claims 1-72, 94-114 or 126, wherein Y is an optionally substituted benzothiophene.

128. The compound of any one of Claims 1-72, 94-114 or 126, wherein Y is an optionally substituted benzofuran or an optionally substituted indole.

129. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 1, 13-1, 100, 101, 102, 103, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116a, 116b, 117, 117a, 117b, 118, 118a, 118b, 119, 120, 120a, 120b, 121, 122, 122a, 122b, 123, 124, 125, 126, 127, 128, 129, 131, 132, 133, 134, 138, 139, 142, 143, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 158, 159, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 218, 219, 221, 223, 224, 225, 226, 227, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 306, 307, 308, 309, 310, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498a, 498b, 498c, 498d, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521,

AMENDED SHEET
IPEA/AU

522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604a, 604b, 604c, 604d, 605a, 605b, 605c, 605d, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623a, 623b, 624a, 624b, 625, 626, 627, 628, 629, 630, 631, 632, 633a, 633b, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 680, 681 and 682, or a pharmaceutically acceptable salt of the foregoing.

130. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 149, 150, 156, 157, 160, 217, 220, 222, 229, 287, 302, 303, 304, 305, 311, 401, 473 and 474, or a pharmaceutically acceptable salt of the foregoing.

131. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 130, 135, 140 and 141, or a pharmaceutically acceptable salt of the foregoing.

132. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 104 and 161, or a pharmaceutically acceptable salt of the foregoing.

133. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 136 and 137, or a pharmaceutically acceptable salt of the foregoing.

134. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

135. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 136 in the preparation of a medicament for ameliorating or treating a paramyxovirus infection.

136. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for inhibiting replication of a paramyxovirus.

AMENDED SHEET
IPEA/AU

137. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for contacting a cell infected with a paramyxovirus.

138. The use of any one of Claims 135-137, wherein the paramyxovirus infection is a human respiratory syncytial virus infection.

139. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for ameliorating or treating a paramyxovirus infection in combination with one or more agents comprising administering or contacting a cell with an effective amount of the compound of any one of Claims 1-135, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 136.

140. The use of Claim 139, wherein the paramyxovirus infection is a human respiratory syncytial virus infection; and wherein the one or more agents is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing.

141. The use of Claim 140, wherein the one or more agents is selected from the group consist of RSV-IGIV, palivizumab, motavizumab, 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one (BMS-433771), 4,4"-bis-{4,6-bis-[3-(bis-carbamoylmethyl-sulfamoyl)-phenylamino]-(1,3,5)triazin-2-ylamino}-biphenyl-2,2"-disulfonic-acid (RFI-641), 4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazine-2-ylamino]-biphenyl-2,2'-disulfonic acid, disodium salt (CL387626), 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]-6-methyl-3-pyridinol (JNJ-2408068), 2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol (TMC-353121), 5,5'-bis[1-(((5-amino-1H-tetrazolyl)imino)methyl)]2,2',4''-methylidynetrisphenol (VP-14637, MDT-637), N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide (P13), 2-((2-((1-(2-aminoethyl)piperidin-4-yl)amino)-4-methyl-1H-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol (R170591), 1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane (C15), (R)-9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydro-1H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5(9bH)-one

AMENDED SHEET
IPEA/AU

(BTA9981), [2,2-bis(docosyloxy-oxymethyl)propyl-5-acetaoamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium-oxysulfonyl)-D-glycero-D-galacto-2-nonulopyranosid]onate (MBX-300), BTA-C286, N-(2-((S)-2-(5-((S)-3-aminopyrrolidin-1-yl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)-4-chlorophenyl)methanesulfonamide (GS-5806), an anti-RSV nanobody, a peptide fusion inhibitor (such as a peptide having the sequence DEFDASISQVNEKINQSLAFIRKSDELL (T-67), a peptide having the sequence FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST (T-118), (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (RSV-604), STP-92, iKT-041, 6-{4-[(biphenyl-2-ylcarbonyl) amino]benzoyl}-N-cyclopropyl-5,6-dihydro-4H-thieno[3,2-d][1]benzazepine-2-carboxamide (YM-53403). N-cyclopropyl-5-(4-(2-(pyrrolidin-1-yl)benzamido)benzoyl)-5,6,7,10-tetrahydrobenzo[b]cyclopenta[d]azepine-9-carboxamide. 6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, 4-amino-8-(3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl)-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-1H-imidazo[4,5-h]-isoquinoline-7,9(6H,8H)-dione, AZ27, ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR), 4-hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide (pyrazofurin), 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide (Taribavirin, viramidine), 1,3,4-thiadiazol-2-ylcyanamide (LY253963), tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (VX-497), (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid (Mycophenolic acid), 2-morpholin-4-ylethyl-(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate (Mycophenolate Mofetil), a Type 1 interferon, a Type 2 interferon, a Type 3 interferon, a double stranded RNA oligonucleotide, 5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide (leflumomide), N-(2-chloro-4-methylphenyl)-2-((1-(4-methoxyphenyl)-1H-benzo[d]imidazol-2-yl)thio)propanamide (JMN3-003), an intratracheal formulation of recombinant human CC10 (CG-100), high titer, human immunoglobulin (RI-001), a non-neutralizing mAb against the G protein (mAb 131-2G), ALN-RSV01, ALN-RSV02, Medi-559, Medi-534 and Medi-557, or a pharmaceutically acceptable salt of the foregoing.

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

$$A—L—Y \quad (I)$$

wherein: L is selected from the group consisting of:


(Ia),


(Ib),


(Ic) and


(Id);

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted 5-18 membered heterocyclyl;

Y is selected from the group consisting of an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{1a}, R^{1b}, R^{1c} and R^{1d} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{2a} and R^{2a1} are each independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or

R^{2a1} is hydrogen, and R^{1a} and R^{2a} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl,

R^{2b} and R^{2b1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or

R^{2b1} is hydrogen, and R^{1b} and R^{2b} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl;

R^{2c} and R^{2c1} are each independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy;

R^{2d} and R^{2d1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy;

-------- between X^{1a} and X^{2a} represents a single or double bond between X^{1a} and X^{2a}; ---------- between X^{2a} and X^{3a} represents a single or double bond between X^{2a} and X^{3a}; provided that ---------- between X^{1a} and X^{2a} and -------- between X^{2a} and X^{3a} cannot be both double bonds and at least one of -------- is a double bond;

when -------- between X^{1a} and X^{2a} represents a double bond and -------- between X^{2a} and X^{3a} is a single bond, then X^{1a} is N or CR^{4a1}, X^{2a} is N or CR^{5a} and X^{3a} is NR^{6a1}, C(=O) or $CR^{6a2}R^{6a3}$; and when -------- between X^{1a} and X^{2a} represents a single bond and -------- between X^{2a} and X^{3a} is a double bond, then X^{1a} is NR^{4a} or $CR^{4a2}R^{4a3}$, X^{2a} is N or CR^{5a} and X^{3a} is N or CR^{6a}; or

X^{1a}, X^{2a} and X^{3a} are each independently C, N or C(=O), and form a ring or ring system selected from an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl by joining X^{1a} and X^{3a} together; with the proviso that the valencies of X^{1a}, X^{2a} and X^{3a} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl, and X^{1a}, X^{2a} and X^{3a} are uncharged;

R^{3a} is selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and ,

R^{3a1} is selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3a} and R^{3a1} cannot be both hydrogen; or

R^{3a} and R^{3a1} together form =N-OR^a; or R^{3a} and R^{3a1} together with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^{4a}, R^{4a1}, R^{4a2} and R^{4a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{5a} and R^{5a1} are each independently be hydrogen or an unsubstituted C_{1-4} alkyl;

R^{6a} and R^{6a1} are each independently hydrogen, an optionally substituted C_{1-4} alkyl or an optionally substituted alkoxyalkyl;

R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

X^{1b}, X^{2b} and X^{3b} are each independently C, N, O or C(=O), and form indicates a bi-cyclic ring selected from an optionally substituted 9-membered bi-cyclic heteroaryl, an optionally substituted 10-membered bi-cyclic heteroaryl, an optionally substituted 9-membered bi-cyclic heterocyclyl and an optionally substituted 10-membered bi-cyclic heterocyclyl by joining X^{1b} and X^{3b} together, wherein -------- between X^{1b} and X^{2b} represents a single or double bond between X^{1b} and X^{2b}; -------- between X^{2b} and X^{3b} represents a single or double bond between X^{2b} and X^{3b}; and provided that at least one of X^{1b}, X^{2b} and X^{3b} comprises a nitrogen atom and both -------- cannot be double bonds; with the proviso that the valencies of X^{1b}, X^{2b} and

X^{3b} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl; and X^{1b}, X^{2b} and X^{3b} are uncharged;

R^{3c} and R^{3c1} are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3c} and R^{3c1} cannot be both hydrogen; or R^{3c} and R^{3c1} together form =N-OR^c; or R^{3c} and R^{3c1} together with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^a and R^c are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{4c} and R^{5c} are taken together to form an unsubstituted aryl, an unsubstituted heteroaryl or an optionally substituted heterocyclyl;

Z^c is N or CH;

m^d is 0 or 1; and

ring B^d is an optionally substituted C_5 cycloalkyl;

ring B^{d1} is an optionally substituted pyridinyl; and

provided that when L is Formula (Ic), then Y is absent; and

provided that the compound is not .

2. The compound of Claim 1, wherein L is Formula (Ia).

3. The compound of Claim 2, wherein X^{1a} is CR^{4a1} or $CR^{4a2}R^{4a3}$, X^{2a} is N, and X^{3a} is CR^{6a} or $CR^{6a2}R^{6a3}$.

4. The compound of Claim 2, wherein ------- between X^{1a} and X^{2a} is a single bond, ------- between X^{2a} and X^{3a} is a double bond, X^{1a} is $CR^{4a2}R^{4a3}$, X^{2a} is N, and X^{3b} is CR^{6a}.

5. The compound of Claim 2, wherein -------- between X^{1a} and X^{2a} is a double bond, -------- between X^{2a} and X^{3a} is a single bond, X^{1a} is CR^{4a1}, X^{2b} is N, and X^{3b} is $CR^{6a2}R^{6a3}$.

6. The compound of Claim 2, wherein -X^{1a}------X^{2a}------X^{3a}- is -CH_2-N=CH- or -CH=N-CH_2-.

7. The compound of Claim 2, wherein -X^{1a}------X^{2a}------X^{3a}- is -N=N-CH_2-, -N=CH-CH_2- or -N=CH-NH-.

8. The compound of Claim 2, wherein -X^{1a}------X^{2a}------X^{3a}- is -CH_2-CH=N-, -NH-CH=NH- or -NH-N=CH-.

9. The compound of Claim 1, wherein L is Formula (Ia1):



.

10. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} form a ring or ring system that is an optionally substituted aryl.

11. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} form a ring or ring system that is an optionally substituted mono-cyclic heteroaryl or an optionally substituted bi-cyclic heteroaryl.

12. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} form a ring or ring system that is an optionally substituted mono-cyclic heterocyclyl or an optionally substituted bi-cyclic heterocyclyl.

13. The compound of Claim 9, wherein X^{1a}, X^{2a} and X^{3a} form a ring or ring system selected from the group consisting of an optionally substituted 

, an optionally substituted 

, an optionally substituted 

, an optionally

substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted ; wherein R^{A1}, R^{A2}, R^{A3} and R^{A4} is each independently hydrogen or an unsubstituted C_{1-6} alkyl; each ------ is independently absent or a bond; each R^{A5}, each R^{A6}, each R^{A7} is independently an unsubstituted C_{1-6} alkyl, halogen, hydroxy, amino, mono-substituted amino, di-substituted amino or –NH-S(=O)C_{1-4} alkyl; and R^{A8} is hydrogen or an unsubstituted C_{1-6} alkyl.

14. The compound of Claim 1, wherein L is Formula (Ia2):



wherein R^{7a1}, R^{7a2} and R^{7a3} are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl, an optionally substituted O-amido and an optionally substituted C-carboxy.

15. The compound of Claim 14, wherein R^{7a1} is a C_{1-4} alkoxy, and R^{7a2} and R^{7a3} are both hydrogen.

16. The compound of Claim 14, wherein R^{7a1} is a hydrogen, R^{7a2} is an optionally substituted C_{1-4} alkyl, and R^{7a3} is hydrogen

17. The compound of Claim 16, wherein the substituted C_{1-4} alkyl of R^{7a2} is substituted with a substituent selected from the group consisting of halo, hydroxy, C_{1-4} alkoxy, an optionally substituted aryl(C_{1-4} alkyl), an optionally substituted C-carboxy, amino, an optionally substituted mono-substituted amino, an optionally substituted di-substituted amino, an optionally substituted C-amido, an optionally substituted N-amido, an optionally substituted N-carbamyl, an optionally substituted N-sulfonamido, an optionally substituted urea, an optionally substituted amidine and an optionally substituted acetylurea.

18. The compound of Claim 14, wherein R^{7a1} is a hydrogen, R^{7a2} is an optionally substituted heterocyclyl, and R^{7a3} is hydrogen

19. The compound of Claim 14, wherein R^{7a1} is a mono-substituted amino, and R^{7a2} and R^{7a3} are both hydrogen.

20. The compound of Claim 1, wherein L is Formula (Ia3):



wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted cycloalkyl an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and R^{8a3} is selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl and an optionally substituted C-carboxy.

21. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered cycloalkyl or an optionally substituted 6-membered cycloalkyl.

22. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted aryl.

23. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered heteroaryl.

24. The compound of Claim 20, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heterocyclyl or an optionally substituted 6-membered heterocyclyl.

25. The compound of Claim 20, wherein  in Formula (Ia3) is an optionally substituted , an optionally substituted  or an optionally substituted ; wherein each ------ is independently absent or a bond; each R^{A5}, each R^{A6}, each R^{A7} is halogen, an unsubstituted C_{1-6} alkyl, hydroxy, amino, an optionally substituted mono-substituted amino, an optionally substituted di-substituted amino, $-(CH_2)_{1-4}OH$, $-(CH_2)_{1-4}NH_2$ or N-sulfinamido (for example, $-NH-S(=O)C_{1-4}$ alkyl), or two R^{A5}, two R^{A6} or two R^{A7} are taken together to form an optionally substituted 5- membered ring to an optionally substituted 6-membered ring; and R^{A8} is hydrogen or an unsubstituted C_{1-6} alkyl.

26. The compound of any one of Claims 2-25, wherein R^{1a} can be hydrogen.

27. The compound of any one of Claims 2-25, wherein R^{1a} can be an unsubstituted C_{1-4} alkyl.

28. The compound of any one of Claims 2-27, wherein R^{2a} and R^{2a1} are both hydrogen.

29. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an unsubstituted C_{1-4} alkyl.

30. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

31. The compound of any one of Claims 2-27, wherein R^{2a} is hydrogen and R^{2a1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

32. The compound of any one of Claims 2-27, wherein R^{2a1} is hydrogen, and R^{1a} and R^{2a} are joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl.

33. The compound of any one of Claims 2-27, wherein R^{2a} and R^{2a1} are both an unsubstituted C_{1-4} alkyl.

34. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

35. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is hydroxy.

36. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen, -O-carboxy, an unsubstituted heteroaryl and an optionally substituted heterocyclyl.

37. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{1-4} alkyl.

38. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{2-4} alkynyl.

39. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is CF_3.

40. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is CHF_2.

41. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is CF_3.

42. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is CHF_2.

43. The compound of any one of Claims 2-33, wherein R^{3a} is hydroxy, and R^{3a1} is an unsubstituted C_{3-6} cycloalkyl.

44. The compound of any one of Claims 2-33, wherein R^{3a} is halogen, and R^{3a1} is an unsubstituted C_{3-6} cycloalkyl.

45. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} are both halogen.

46. The compound of any one of Claims 2-33, wherein R^{3a} is hydrogen, and R^{3a1} is unsubstituted C_{1-4} alkyl.

47. The compound of any one of Claims 2-33, wherein R^{3a} is an unsubstituted C_{1-4} alkoxy, and R^{3a1} is an unsubstituted C_{1-4} alkyl.

48. The compound of any one of Claims 2-33, wherein R^{3a1} is a substituted C_{1-4} alkyl substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, mono-substituted amino, di-substituted amino, -N-amido, an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl; and the other of R^{3a} and R^{3a1} is hydroxy.

49. The compound of any one of Claims 2-33, wherein one of R^{3a} and R^{3a1} is an optionally substituted mono-cyclic heteroaryl or an optionally substituted mono-cyclic heterocyclyl; and the other of R^{3a} and R^{3a1} is hydroxy.

50. The compound of Claim 49, wherein one of R^{3a} and R^{3a1} is selected from the group consisting of an optionally substituted imidazole, an optionally substituted pyrazole, an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted morpholine, an optionally substituted triazole, an optionally substituted piperazinone and an optionally substituted azetidine; and the other of R^{3a} and R^{3a1} is hydroxy.

51. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} together form $N{=}OR^{a}$.

52. The compound of any one of Claims 2-33, wherein R^{3a} and R^{3a1} are join together with the atom to which they are attached to form an optionally substituted 3 to 6 membered ring.

53. The compound of Claim 1, wherein L is Formula (Ib):



54. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted 9-membered bi-cyclic heteroaryl or an optionally substituted 10-membered bi-cyclic heteroaryl.

55. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted 9-membered bi-cyclic heterocyclyl or an optionally substituted 10-membered bi-cyclic heterocyclyl.

56. The compound of any one of Claims 53-55, wherein X^{1b} is C, X^{2b} is N and X^{3b} is C.

57. The compound of any one of Claims 53-55, wherein X^{1b} is N, X^{2b} is N and X^{3b} is C.

58. The compound of any one of Claims 53-55, wherein X^{1b} is N or C, X^{2b} is C(=O) or O and X^{3b} is N or C.

59. The compound of Claim 53, wherein the bi-cyclic ring is an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein each ----- is independently absent or a bond; each R^{B1}, each R^{B2} and each R^{B3} is an unsubstituted C_{1-6} alkyl, halogen, hydroxy, amino, mono-substituted amino, di-substituted amino or –NH-S(=O)C_{1-4} alkyl; and R^{B4} is hydrogen or an unsubstituted C_{1-6} alkyl.

60. The compound of Claim 1, wherein L is Formula (Ib1):



wherein: the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted cycloalkenyl an optionally substituted aryl, an

optionally substituted heteroaryl or an optionally substituted heterocyclyl; and R^{4b3} is selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl and an optionally substituted C-carboxy.

61. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered cycloalkenyl or an optionally substituted 6-membered cycloalkenyl.

62. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted aryl.

63. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered heteroaryl.

64. The compound of Claim 60, wherein the dashed semi-circle along with the two carbon atoms to which it is connected form an optionally substituted 5-membered heterocyclyl or an optionally substituted 6-membered heterocyclyl.

65. The compound of any one of Claims 53-64, wherein R^{1b} is hydrogen.

66. The compound of any one of Claims 53-64, wherein R^{1b} is unsubstituted C_{1-4} alkyl.

67. The compound of any one of Claims 63-56, wherein R^{2b} and R^{2b1} are both hydrogen.

68. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an optionally substituted C_{1-4} alkyl.

69. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

70. The compound of any one of Claims 53-66, wherein R^{2b} is hydrogen and R^{2b1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

71. The compound of any one of Claims 53-66, wherein R^{2b1} is hydrogen, and R^{1b} and R^{2b} are joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl.

72. The compound of any one of Claims 53-66, wherein R^{2b} and R^{2b1} are both an optionally substituted C_{1-4} alkyl.

73. The compound of Claim 1, wherein L is Formula (Ic):



74. The compound of Claim 73, wherein R^{1c} is hydrogen.

75. The compound of Claim 73, wherein R^{1c} is an unsubstituted C_{1-4} alkyl.

76. The compound of any one of Claims 73-75, wherein R^{2c} and R^{2c1} are both hydrogen.

77. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an unsubstituted C_{1-4} alkyl.

78. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

79. The compound of any one of Claims 73-75, wherein R^{2c} is hydrogen and R^{2c1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

80. The compound of any one of Claims 73-75, wherein R^{2c} and R^{2c1} are both an unsubstituted C_{1-4} alkyl.

81. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

82. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is hydroxy.

83. The compound of any one of Claims 73-80, wherein R^{3c} is hydroxy, and R^{3c1} is selected from the group consisting of amino, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{2-4}

alkenyl, an unsubstituted C_{2-4} alkynyl, an unsubstituted C_{3-6} cycloalkyl, an unsubstituted C_{1-4} alkoxy, hydroxy, halogen and an unsubstituted heteroaryl.

84. The compound of any one of Claims 73-80, wherein R^{3c} is hydroxy, and R^{3c1} is an unsubstituted C_{1-4} alkyl.

85. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} are both halogen.

86. The compound of any one of Claims 73-80, wherein R^{3c} is hydrogen, and R^{3c1} is unsubstituted C_{1-4} alkyl.

87. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} together form $N=OR^{c}$.

88. The compound of any one of Claims 73-80, wherein R^{3c} and R^{3c1} join together with the atom to which they are attached to form an optionally substituted 3 to 6 membered ring.

89. The compound of any one of Claims 73-88, wherein Z^{c} is N.

90. The compound of any one of Claims 73-88, wherein Z^{c} is CH.

91. The compound of any one of Claims 73-90, wherein R^{4c} and R^{5c} are taken together to form an unsubstituted aryl or an unsubstituted heteroaryl.

92. The compound of any one of Claims 73-90, wherein R^{4c} and R^{5c} are taken together to form an optionally substituted heterocyclyl.

93. The compound of Claim 92, wherein the optionally substituted heterocyclyl is an optionally substituted, 

wherein * each indicate a point of attachment to the piperdinyl ring.

94. The compound of Claim 1, wherein L is Formula (Id):



95. The compound of Claim 94, wherein m^{d} is 0 or 1.

96. The compound of Claim 94, wherein ring B^d is an optionally substituted C_5 cycloalkyl.

97. The compound of any one of Claims 94-96, wherein R^{1d} is hydrogen.

98. The compound of any one of Claims 94-96, wherein R^{1d} is unsubstituted C_{1-4} alkyl.

99. The compound of any one of Claims 94-98, wherein R^{2d} and R^{2d1} are both hydrogen.

100. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an optionally substituted C_{1-4} alkyl.

101. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an optionally substituted aryl(C_{1-6} alkyl) or an optionally substituted heterocyclyl(C_{1-6} alkyl).

102. The compound of any one of Claims 94-98, wherein R^{2d} is hydrogen and R^{2d1} is an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

103. The compound of any one of Claims 94-98, wherein R^{2c} and R^{2c1} are both an optionally substituted C_{1-4} alkyl.

104. The compound of any one of Claims 1-103, wherein A is an optionally substituted aryl.

105. The compound of Claim 104, wherein A is an optionally substituted phenyl.

106. The compound of Claim 105, wherein A is a phenyl substituted with one or more substituents selected from the group consisting of: an unsubstituted C_{1-4} alkyl, an optionally substituted C_{1-4} alkyl, cycloalkyl, hydroxy, an optionally substituted C_{1-4} alkoxy, C_{1-4} alkoxy, halogen, haloalkyl, an optionally substituted haloalkoxy, nitro, amino, mono-substituted amino, di-substituted amine, -O-amido, sulfenyl, alkyoxyalkyl, an optionally substituted aryl, an optionally substituted mono-cyclic heteroaryl, an optionally substituted mono-cyclic heterocyclyl, an optionally substituted aryl(C_{1-4} alkyl), an optionally substituted monocyclic heteroaryl(C_{1-4} alkyl), an optionally substituted monocyclic heterocyclyl(C_{1-4} alkyl), hydroxyalkyl and aminoalkyl.

107. The compound of Claim 105, wherein A is a phenyl substituted with one or more substituents selected from the group consisting of: methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, phenoxy, bromo, chloro, fluoro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, cyano, N,N-di-methyl-amine,

N,N-di-ethyl-amine, N-methyl-N-ethyl-amine, N-methyl-amino, N-ethyl-amino, amino, N-amido , N-sulfonamido, alkylthio, an optionally substituted phenyl, an optionally substituted imidazole, an optionally substituted morpholinyl, an optionally substituted pyrazole, an optionally substituted pyrrolidinyl, an optionally substituted pyridinyl, an optionally substituted piperidinyl, an optionally substituted piperidinone, an optionally substituted pyrrolidinone, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted 1,2,4-oxadiazole, $-(CH_2)_{1-4}$-OH, $-(CH_2)_{1-2}$-$NH(CH_3)$, an optionally substituted $-(CH_2)_{1-2}$-imidazole, an optionally substituted $-(CH_2)_{1-2}$-pyrrolidinone, an optionally substituted $-(CH_2)_{1-2}$-imidazolidinone, $-O(CH_2)_2$-NH_2, $-O(CH_2)_2$-$NH(CH_3)$, $-O(CH_2)_2$-$N(CH_3)_2$, -O-$(CH_2)_{2-4}$OH, -$O(CH_2)_2OCH_3$, an optionally substituted $-O(CH_2)_{0-2}$-cyclopentanone, an optionally substituted -$O(CH_2)_{0-2}$pyrrolidinone, an optionally substituted $-O(CH_2)_{0-2}$-morpholinyl, an optionally substituted $-O(CH_2)_{0-2}$-triazole, an optionally substituted $-O(CH_2)_{0-2}$-imidazole, an optionally substituted $-O(CH_2)_{0-2}$-pyrazole, an optionally substituted $-O(CH_2)_{0-2}$-tetrahydrofuran, an optionally substituted $-O(CH_2)_{0-2}$-pyrrolidinone, an optionally substituted $-O(CH_2)_{0-2}$-tetrazole, an optionally substituted $-O(CH_2)_{0-2}$-tetrazolone,




,

,

,

,

and

.

108. The compound of any one of Claims 105-107, wherein A is a di-substituted phenyl.

109. The compound of any one of Claims 1-103, wherein A is an optionally substituted cycloalkyl or an optionally substituted cycloalkenyl.

110. The compound of any one of Claims 1-103, wherein A is an optionally substituted aryl(C_{1-2} alkyl).

111. The compound of any one of Claims 1-103, wherein A is an optionally substituted heteroaryl.

112. The compound of Claim 111, wherein the optionally substituted heteroaryl is selected from the group consisting of: an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted quinolone, an optionally substituted imidazole, an optionally substituted oxazole, an optionally substituted isoxazole, an optionally substituted benzoimidazole, an optionally substituted benzooxazole, an optionally substituted benzothiazole and an optionally substituted imidazo[1,2-a]pyrimidine.

113. The compound of any one of Claims 1-103, wherein A is an optionally substituted 5-18 membered heterocyclyl.

114. The compound of Claim 113, wherein the optionally substituted 5-18 membered heterocyclyl is selected from the group consisting of: an optionally substituted

, an optionally substituted

, an optionally substituted

, an optionally substituted

, an optionally substituted

,

an optionally substituted , optionally substituted  and an optionally substituted .

115. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted aryl.

116. The compound of Claim 115, wherein Y is a mono-substituted phenyl.

117. The compound of Claim 116, wherein Y is a di-substituted phenyl.

118. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted mono-cyclic heteroaryl.

119. The compound of Claim 118, wherein the optionally substituted mono-cyclic heteroaryl is selected from the group consisting of: an optionally substituted imidazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted pyridine, an optionally substituted pyrazole, an optionally substituted oxazole, an optionally substituted isoxazole and an optionally substituted thiazole.

120. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted bi-cyclic heteroaryl.

121. The compound of Claim 120, wherein the optionally substituted bi-cyclic heteroaryl is selected from the group consisting of: an optionally substituted benzothiophene, an optionally substituted benzofuran, an optionally substituted indole, an optionally substituted quinoline, an optionally substituted isoquinoline, an optionally substituted benzooxazole, an optionally substituted benzoisoxazole, an optionally substituted benzoisothiazole, an optionally substituted benzothiazole, an optionally substituted benzoimidazole, an optionally substituted benzotriazole, an optionally substituted 1H-indazole, an optionally substituted 2H-indazole, an optionally substituted , an optionally substituted , an optionally

substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , and an optionally substituted .

122. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted heterocyclyl.

123. The compound of Claim 122, wherein the optionally substituted heterocyclyl is selected from the group consisting of: an optionally substituted pyridinone, an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted .

124. The compound of any one of Claims 1-72 or 94-114, wherein Y is an optionally substituted cycloalkenyl.

125. The compound of any one of Claims 1-72, 92-115 or 118-124, wherein Y is unsubstituted.

126. The compound of any one of Claims 1-72 or 94-124, wherein Y is substituted with one or more R^B, wherein each R^B is independently selected from the group consisting of: cyano, halogen, an optionally substituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an optionally substituted aryl, an optionally substituted 5 or 6

membered heteroaryl, an optionally substituted 5 or 6 membered heterocyclyl, hydroxy, C_{1-4} alkoxy, alkoxyalkyl, C_{1-4} haloalkyl, haloalkoxy, an unsubstituted acyl, an optionally substituted –C-carboxy, an optionally substituted –C-amido, sulfonyl, carbonyl, amino, mono-substituted amine, di-substituted amine and .

127. The compound of any one of Claims 1-72, 94-114 or 126, wherein Y is an optionally substituted benzothiophene.

128. The compound of any one of Claims 1-72, 94-114 or 126, wherein Y is an optionally substituted benzofuran or an optionally substituted indole.

129. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 1, 13-1, 100, 101, 102, 103, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 116a, 116b, 117, 117a, 117b, 118, 118a, 118b, 119, 120, 120a, 120b, 121, 122, 122a, 122b, 123, 124, 125, 126, 127, 128, 129, 131, 132, 133, 134, 138, 139, 142, 143, 144, 145, 146, 147, 148, 151, 152, 153, 154, 155, 158, 159, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 218, 219, 221, 223, 224, 225, 226, 227, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 306, 307, 308, 309, 310, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487,

488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498a, 498b, 498c, 498d, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604a, 604b, 604c, 604d, 605a, 605b, 605c, 605d, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623a, 623b, 624a, 624b, 625, 626, 627, 628, 629, 630, 631, 632, 633a, 633b, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 680, 681 and 682, or a pharmaceutically acceptable salt of the foregoing.

130. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 149, 150, 156, 157, 160, 217, 220, 222, 229, 287, 302, 303, 304, 305, 311, 401, 473 and 474, or a pharmaceutically acceptable salt of the foregoing.

131. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 130, 135, 140 and 141, or a pharmaceutically acceptable salt of the foregoing.

132. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 104 and 161, or a pharmaceutically acceptable salt of the foregoing.

133. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of: 136 and 137, or a pharmaceutically acceptable salt of the foregoing.

134. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

135. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 136 in the preparation of a medicament for ameliorating or treating a paramyxovirus infection.

136. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for inhibiting replication of a paramyxovirus.

137. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for contacting a cell infected with a paramyxovirus.

138. The use of any one of Claims 135-137, wherein the paramyxovirus infection is a human respiratory syncytial virus infection.

139. Use of an effective amount of a compound of any one of Claims 1-133, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 134 in the preparation of a medicament for ameliorating or treating a paramyxovirus infection in combination with one or more agents comprising administering or contacting a cell with an effective amount of the compound of any one of Claims 1-135, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 136.

140. The use of Claim 139, wherein the paramyxovirus infection is a human respiratory syncytial virus infection; and wherein the one or more agents is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing.

141. The use of Claim 140, wherein the one or more agents is selected from the group consist of RSV-IGIV, palivizumab, motavizumab, 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one (BMS-433771), 4,4"-bis-{4,6-bis-[3-(bis-carbamoylmethyl-sulfamoyl)-phenylamino]-(1,3,5)triazin-2-ylamino}-biphenyl-2,2"-disulfonic-acid (RFI-641), 4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazine-2-ylamino]-biphenyl-2,2'-disulfonic acid, disodium salt (CL387626), 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]-6-methyl-3-pyridinol (JNJ-2408068), 2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol (TMC-353121), 5,5′-bis[1-(((5-amino-1H-tetrazolyl)imino)methyl)]2,2′,4″-methylidynetrisphenol (VP-14637, MDT-637), N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide (P13), 2-((2-((1-(2-aminoethyl)piperidin-4-yl)amino)-4-methyl-1H-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol (R170591), 1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane (C15), (R)-9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydro-1H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5(9bH)-one

(BTA9981), [2,2-bis(docosyloxy-oxymethyl)propyl-5-acetaoamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium-oxysulfonyl)-D-glycero-D-galacto-2-nonulopyranosid]onate (MBX-300), BTA-C286, N-(2-((S)-2-(5-((S)-3-aminopyrrolidin-1-yl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)-4-chlorophenyl)methanesulfonamide (GS-5806), an anti-RSV nanobody, a peptide fusion inhibitor (such as a peptide having the sequence DEFDASISQVNEKINQSLAFIRKSDELL (T-67), a peptide having the sequence FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST (T-118), (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (RSV-604), STP-92, iKT-041, 6-{4-[(biphenyl-2-ylcarbonyl) amino]benzoyl}-N-cyclopropyl-5,6-dihydro-4H-thieno[3,2-d][1]benzazepine-2-carboxamide (YM-53403). N-cyclopropyl-5-(4-(2-(pyrrolidin-1-yl)benzamido)benzoyl)-5,6,7,10-tetrahydrobenzo[b]cyclopenta[d]azepine-9-carboxamide. 6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, 4-amino-8-(3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl)-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-1H-imidazo[4,5-h]-isoquinoline-7,9(6H,8H)-dione, AZ27, ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR), 4-hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide (pyrazofurin), 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide (Taribavirin, viramidine), 1,3,4-thiadiazol-2-ylcyanamide (LY253963), tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (VX-497), (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid (Mycophenolic acid), 2-morpholin-4-ylethyl-(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate (Mycophenolate Mofetil), a Type 1 interferon, a Type 2 interferon, a Type 3 interferon, a double stranded RNA oligonucleotide, 5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide (leflumomide), N-(2-chloro-4-methylphenyl)-2-((1-(4-methoxyphenyl)-1H-benzo[d]imidazol-2-yl)thio)propanamide (JMN3-003), an intratracheal formulation of recombinant human CC10 (CG-100), high titer, human immunoglobulin (RI-001), a non-neutralizing mAb against the G protein (mAb 131-2G), ALN-RSV01, ALN-RSV02, Medi-559, Medi-534 and Medi-557, or a pharmaceutically acceptable salt of the foregoing.